A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

H ealth officials in the UK are launching an investigation into weight loss drugs after hundreds of consumers reported ...

CRISPRware is a new tool scientists can use to design the best guide RNAs to edit genes in many organisms, without the need for deep bioinformatics expertise. By making gene editing more precise and ...

Does using Ozempic cause brain fog? It depends on who you ask. This article takes a closer look at what’s going on with ...

Essex mother Camilla Do Rosario told her TikTok followers the one piece of advice she wishes she knew before embarking on a ...

An Ozempic-like drug prescribed for diabetes has been found to reduce the frequency of debilitating migraine. Researchers say ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Ecnoglutide is a novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist shown to cause sustained weight loss.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.